Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05379101 · ClinicalTrials.gov registry record

Intracardiac Flow Assessment in Cardiac Amyloidosis

A clinical trial of Healthy Adults and Amyloidosis Cardiac, sponsored by Mayo Clinic.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT05379101 is a study of Healthy Adults and Amyloidosis Cardiac that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, above the 83-participant average among 33 other Healthy Adults trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05379101, a study of Healthy Adults and Amyloidosis Cardiac, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.

Interventions

  • DIAGNOSTIC_TEST Cardiac magnetic resonance image (CMR)
  • DIAGNOSTIC_TEST Transthoracic Echocardiogram (TTE)
  • DIAGNOSTIC_TEST Six-minute Walk Test

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-07-20
Est. Completion 2026-06

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT05379101

The ClinicalTrials.gov registry entry for NCT05379101 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 33 other Healthy Adults trials with a reported enrollment target (20% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Adults appearing as the primary indexed condition, and to 3 interventions - of which Cardiac magnetic resonance image (CMR) is the first listed.

NCT05379101 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05379101 about?

NCT05379101 is a clinical study titled "Intracardiac Flow Assessment in Cardiac Amyloidosis". The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.

What is the current status of trial NCT05379101?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-07-20. Estimated completion is 2026-06.

What conditions does trial NCT05379101 study?

This clinical trial studies the following conditions: Healthy Adults, Amyloidosis Cardiac.

What interventions are being tested in trial NCT05379101?

The interventions under investigation include: Cardiac magnetic resonance image (CMR) (DIAGNOSTIC_TEST), Transthoracic Echocardiogram (TTE) (DIAGNOSTIC_TEST), Six-minute Walk Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05379101?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05379101 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.